The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

Vimseltinib is the first and only therapy with a positive CHMP opinion for the treatment of TGCT in the European Union Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discoverin ...

Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products for Human Use (CHMP) has ...

ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...

Antigen-Specific Response: Activated T cells demonstrated selective cytotoxicity against pancreatic tumor cells while sparing unrelated cell types. Scalable, Off-the-Shelf Platform: The use of CD34⁺ ...

Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy Provided by ACCESS Newswire Jul 17, 2025, 6:15:00 AM ...

Pan-cancer intratumour heterogeneity (ITH) characteristics and their relationship with clinical prognosis have not been fully investigated. In this study, we in ...

Delays in starting tocilizumab therapy for giant cell arteritis are caused partly by delays in insurance approval, and costs vary by insurance type, study finds.

Predicting Tumor Response to Neoadjuvant Chemotherapy Based on Pretreatment 18 F-FDG PET/CT Parameters in Locally Advanced Oral Squamous Cell Carcinoma Zhengquan Hu, Tingting Long, Jian Li, Yulai Li, ...